Jazz Pharmaceuticals, Inc. v. Avadel CNS Pharmaceuticals, LLC

  1. February 24, 2023

    Fed. Circ. Won't Let Jazz Keep System Patent In Orange Book

    Jazz Pharmaceuticals must remove a patent from the Orange Book listing for its blockbuster narcolepsy drug Xyrem, as it covers neither the drug itself nor a method of using it, the Federal Circuit concluded Friday.

  2. February 14, 2023

    Jazz Argues Drug Patent Should Stay In Orange Book

    Jazz Pharmaceuticals tried to convince the Federal Circuit in oral arguments on Tuesday to overturn a lower court order to remove its patent for its narcolepsy drug from the Food and Drug Administration's Orange Book, but the judges questioned if Jazz was overcomplicating the case.

  3. January 17, 2023

    Fed. Circ. Urged Not To Reverse Jazz's Orange Book Delisting

    Avadel CNS Pharmaceuticals LLC has asked the Federal Circuit to immediately remove patent protection for Jazz Pharmaceuticals' narcolepsy drug even though Jazz is appealing a district court order to delist a patent for the treatment, arguing access to Avadel's version of the drug would be "life-changing" for patients.

  4. January 02, 2023

    Health Care & Life Sciences Litigation To Watch In 2023

    Before the New Year's Eve confetti has even been swept up, lawyers specializing in health care and life sciences already have enough litigation to keep them busy for much of 2023, which is kicking off with federal courts eyeing suits that carry sweeping significance for administrative law, the False Claims Act, drug approvals, the opioid crisis and abortion rights.

  5. December 19, 2022

    Jazz Pharma Asks Fed. Circ. To Reverse Orange Book Delisting

    Jazz Pharmaceuticals Inc. has urged the Federal Circuit to undo a federal injunction forcing it to delist a narcolepsy drug-related patent from the U.S. Food and Drug Administration's Orange Book, a database of patented drugs, arguing that the district judge misinterpreted the claimed method and federal listing requirements.

  6. December 14, 2022

    Fed. Circ. Pauses 'Orange Book' Delisting For Jazz Drug

    Jazz Pharmaceuticals will be allowed to list its patent for a narcolepsy drug in health regulators' roster of approved drugs, at least for the near future, after the Federal Circuit granted the company's request to extend a stay of the delistment order Wednesday.

  7. December 05, 2022

    Del. Court Won't Pause 'Orange Book' Delisting

    A Delaware federal court on Monday refused to pause an order requiring Jazz Pharmaceuticals to remove a patent for a narcolepsy drug from health regulators' listing of approved drugs, but the Federal Circuit is still considering a bid to stay the order.